Perioperative endocrine–metabolic biomarkers for treatment stratification in glioblastoma: linking systemic dynamics to myeloid immune states

Adult IDH-wildtype glioblastoma remains largely resistant to immunotherapy, even though selected patients develop measurable immune responses. Treatment begins within a rapidly changing perioperative endocrine and metabolic environment. Glioblastoma resection, dexamethasone, acute stress, dysglycemia, altered nutrition, infection, and tissue repair can reshape systemic metabolism and immune-cell composition within hours, while residual glioblastoma tissue undergoes spatially heterogeneous myeloid remodeling over days to weeks. This Review evaluates perioperative exposures, routine blood measures, circulating multi-omics, extracellular vesicles, paired blood-tissue analyses, and mechanistic studies of myeloid immunometabolism in adult IDH-wildtype glioblastoma. Dexamethasone exposure, glycemic status, and blood-derived inflammatory indices are clinically accessible, but most reported associations remain confounded and do not define treatment thresholds. Longitudinal lipidomic, metabolomic, proteomic, and cellular measurements can detect treatment-related state transitions; without standardized timing and tissue anchoring, however, their biological sources remain uncertain. Mechanistic studies connect glucose-lactate signaling, histone lactylation, lipid handling, hypoxia, and cell-of-origin transitions with myeloid suppression, but therapeutic evidence is still largely preclinical. We therefore propose an exposure-time-compartment-biology-decision framework for glioblastoma biomarker development. Its present role is to strengthen trial stratification, confounding control, and pharmacodynamic interpretation, not to justify unvalidated dexamethasone adjustment, immunotherapy selection, or vaccine timing at the bedside.

Authors

Institutions

Publication Details

Journal
Frontiers in Endocrinology
Published
2026-11-16
DOI
https://doi.org/10.3389/fendo.2026.2022519
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Perioperative endocrine–metabolic biomarkers for treatment stratification in glioblastoma: linking systemic dynamics to myeloid immune states

Peizhi Zhou, Wenyi Zhan, Lirui Dai
3 links
Frontiers in Endocrinology
Glioma Diagnosis and Treatment
article

Perioperative endocrine–metabolic biomarkers for treatment stratification in glioblastoma: linking systemic dynamics to myeloid immune states

Peizhi Zhou, Wenyi Zhan, Lirui Dai
article en

Abstract

Adult IDH-wildtype glioblastoma remains largely resistant to immunotherapy, even though selected patients develop measurable immune responses. Treatment begins within a rapidly changing perioperative endocrine and metabolic environment. Glioblastoma resection, dexamethasone, acute stress, dysglycemia, altered nutrition, infection, and tissue repair can reshape systemic metabolism and immune-cell composition within hours, while residual glioblastoma tissue undergoes spatially heterogeneous myeloid remodeling over days to weeks. This Review evaluates perioperative exposures, routine blood measures, circulating multi-omics, extracellular vesicles, paired blood-tissue analyses, and mechanistic studies of myeloid immunometabolism in adult IDH-wildtype glioblastoma. Dexamethasone exposure, glycemic status, and blood-derived inflammatory indices are clinically accessible, but most reported associations remain confounded and do not define treatment thresholds. Longitudinal lipidomic, metabolomic, proteomic, and cellular measurements can detect treatment-related state transitions; without standardized timing and tissue anchoring, however, their biological sources remain uncertain. Mechanistic studies connect glucose-lactate signaling, histone lactylation, lipid handling, hypoxia, and cell-of-origin transitions with myeloid suppression, but therapeutic evidence is still largely preclinical. We therefore propose an exposure-time-compartment-biology-decision framework for glioblastoma biomarker development. Its present role is to strengthen trial stratification, confounding control, and pharmacodynamic interpretation, not to justify unvalidated dexamethasone adjustment, immunotherapy selection, or vaccine timing at the bedside.

Frontiers in EndocrinologyVol. 17
Sichuan University (CN), West China Hospital of Sichuan University (CN)
Department of Science and Technology of Sichuan Province
Good health and well-being
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon